Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 245 • 2019 ACR/ARP Annual Meeting
Comorbidities, Health Care Utilization, and Cost of Care in Systematic Lupus Erythematous Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015
Miao Jiang¹, Aimee Near ², Barnabas Desta ¹, Xia Wang ¹ and Edward Hammond ¹, ¹AstraZeneca, Gaithersburg, MD, ²IQVIA, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with high economic burden. This real-world study assessed health care resource utilization (HRU) and costs in a US…
Abstract Number: 682 • 2019 ACR/ARP Annual Meeting
Correlation Between the Lupus Foundation of America – Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) and Health-Related Quality of Life (HRQoL) and Other PROs in a Primarily Mestizo Population
Manuel Ugarte-Gil¹, Rocío-V. Gamboa-Cárdenas ², Victor Pimentel-Quiroz ³, Cristina Reátegui-Sokolova ⁴, Paola Zeña-Huancas ², Mariela Medina ², Claudia Elera-Fitzcarrald ¹, Luciana Gil ², Samira García ⁴, Francisco Zevallos ⁴, Cesar Pastor-Asurza ⁴, Zoila Rodríguez-Bellido ², Anca Askanase ⁵, Joan Merrill ⁶, Graciela Alarcón ⁷ and Risto Perich-Campos ², ¹Universidad Científica del Sur, Lima, Peru, ²Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Lima, Peru, ³Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁵Columbia University, New York, ⁶Oklahoma Medical Research Foundation, Oklahoma City, ⁷University of Alabama at Birmingham, Birmingham
Background/Purpose: Disease activity in systemic lupus erythematosus (SLE) is understood differently by patients and physicians; furthermore, there are no reliable measures for patients to assess…
Abstract Number: 943 • 2019 ACR/ARP Annual Meeting
A Phase 1b/2a Trial of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
Sarfaraz Hasni¹, Sarthak Gupta ², Michael Davis ³, Elaine Poncio ⁴, Yenealem Temesgen-Oyelakin ⁴, Phillip Carlucci ⁴, Xinghao Wang ⁴, Mohammad Naqi ⁴, Martin Playford ⁵, Rishi Goel ⁴, Xiaobai Li ⁶, Ann Biehl ⁴, Isabel Ochoa-Navas ⁴, Zerai Manna ⁴, Yinghui Shi ⁷, Don Thomas ⁸, Jinguo Chen ⁹, Angélique Biancotto ⁹, Richard Apps ⁹, Foo Cheung ⁹, Yuri Kotliarov ⁹, Ashley Babyak ⁶, Katie Stagliano ⁹, John Tsang ⁹, Wanxia Tsai ¹⁰, Laura Vian ¹⁰, Nathalia Gazaniga ⁴, Valentina Giudice ⁴, Stephen Brooks ¹¹, Meggan Mackay ¹², Peter Gregersen ¹³, Betty Diamond ¹⁴, Nehal Mehta ¹⁵, Alan Remaley ⁵, John O'Shea ¹⁶, Massimo Gadina ¹⁰ and Mariana Kaplan ¹⁶, ¹National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda, MD, ²Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, ³NIAMS/NIH, Bethesda, MD, ⁴NIAMS/NIH, Bethesda, ⁵NHLBI/NIH, Bethesda, ⁶Clinical Center/NIH, Bethesda, ⁷Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁸Walter Reed National Military Medical Center, Bethesda, MD, ⁹NIAID/NIH, Bethesda, ¹⁰Translational Immunology Section, NIAMS, NIH, Bethesda, MD, ¹¹Biomining and Discovery Section/NIAMS/NIH, Bethesda, MD, ¹²Feinstein Institute for Medical Research, New York, ¹³Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁴Feinstein Institutes of Medical Research, Manhasset, NY, ¹⁵National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA, Bethesda, MD, ¹⁶National Institute of Arthritis, Musculoskeletal, and Skin diseases/ National Institutes of Health, Bethesda
Background/Purpose: A pharmacologic intervention that modulates JAK/STAT signaling pathways represents a novel approach for the treatment of Systemic Lupus Erythematosus (SLE). In animal models of…
Abstract Number: 1103 • 2019 ACR/ARP Annual Meeting
Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE), Patient Healthcare Utilization and Characteristics by Major Health Insurance Types in the US
Yiting Wang¹, Laura Hester ¹, Jennifer Lofland ², Shawn Rose ³, Chetan Karyekar ⁴, Dave Kern ⁵, Margaret Blacketer ¹, Kourtney Davis ¹ and Kimberly Shields-Tuttle ⁶, ¹Janssen Research & Development, LLC, Titusville, ²Janssen Scientific Affairs, LLC, Spring House, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Global Services, LLC, Horsham, PA, ⁵Janssen Scientific Affairs, Titusville, ⁶Janssen Research & Development, LLC, Spring House
Background/Purpose: One study estimated that between 161,000 and 322,000 people in the US had definite or probable SLE, based on data from the period of…
Abstract Number: 1565 • 2019 ACR/ARP Annual Meeting
Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Framingham and Modified Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus
Jagan Sivakumaran¹, Paula Harvey ², Ahmed Omar ³, Murray Urowitz ³, Dafna Gladman ⁴, Nicole Anderson ³, Jiandong Su ³ and Zahi Touma ³, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is recognized as an independent risk factor for cardiovascular disease (CVD). This study aimed to determine which cardiovascular risk assessment…
Abstract Number: 1607 • 2019 ACR/ARP Annual Meeting
Risk Factors for Avascular Necrosis in SLE: A Multivariate Model
Romy Kallas¹, Jessica Li ¹ and Michelle Petri ¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Systemic lupus erythematosus patients, particularly those who received corticosteroids are at high risk of avascular necrosis (AVN). A past meta-analysis identified other risk factors…
Abstract Number: 1782 • 2019 ACR/ARP Annual Meeting
A Human SLE Variant NCF1-R90H Drives Lupus-like Kidney Disease in a Pristane-induced Murine Lupus Model
Lin-Yu Geng¹, Ivan Molano ², Ling-Xiao Xu ³, Qing Sun ¹, Phillip Ruiz ⁴, Quan-Zhen Li ⁵, Gary Gilkeson ⁶ and Betty Tsao ⁷, ¹Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ²Division of Rheumatology & Immunology/Medical University of South Carolina, Charelston, ³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charelston, SC, ⁴Department of Surgery/University of Miami School of Medicine, Charleston, ⁵Department of Immunology & Internal Medicine/University of Texas Southwestern Medical Center, Charleston, ⁶Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC, ⁷Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston
Background/Purpose: We previously identify a p.Arg90His (p.R90H) substitution encoded in phagocyte neutrophil cytosolic factor (NCF1) as a novel risk variant for SLE, with decreased and…
Abstract Number: 2029 • 2019 ACR/ARP Annual Meeting
Aberrant H3K9me3 Modification in Promoter Region Up-regulates cAMP Response Element Modulator Alpha in Systemic Lupus Erythematosus
Huilin Zhang ¹ and Qing Zhang², ¹Clinical Nursing Teaching and Research Section, Second Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic), ²Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China (People's Republic)
Background/Purpose: In recent years, accumulating evidences have demonstrated that increased cAMP response element modulator α (CREMα) which can inhibit IL-2 and induce IL-17A in CD4+…
Abstract Number: 2516 • 2019 ACR/ARP Annual Meeting
Development of a Biomarker Panel for Prediction of Disease Flares in Systemic Lupus Erythematosus
Serena Fasano¹, Luciana Pierro ¹, Alessia Borgia ¹, Melania Coscia ¹, Ranieri Formica ¹, antonella Riccardi ¹ and Francesco Ciccia ¹, ¹University of Campania L. Vanvitelli, Naples, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease with a relapsing-remitting course. Uncontrolled lupus flares might lead to organ damage. The routinely performed biomarkers…
Abstract Number: 2548 • 2019 ACR/ARP Annual Meeting
Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity
Aikaterini Thanou¹, Cristina Arriens ², Teresa Aberle ¹, Heather Miller ¹, Lydia Mitchell ³, Stan Kamp ¹, Anca Askanase ⁴, Stavros Stavrakis ⁵, Judith James ² and Joan T. Merrill ⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Columbia University, New York, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, ⁶Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Abatacept (ABA) is a fusion protein of the extracellular domain of CTLA4 and human IgG1-Fc, constructed to inhibit B/T cell co-stimulation. Previous studies of…
Abstract Number: 2742 • 2019 ACR/ARP Annual Meeting
Toward a Liquid Biopsy for Lupus Nephritis: Urine Proteomic Analysis of SLE Identifies Inflammatory and Macrophage Signatures
Andrea Fava¹, Yuji Zhang ², Jill Buyon ³, H. Michael Belmont ⁴, Peter Izmirly ⁵, Chandra Mohan ⁶, Ting Zhang ⁷, The Accelerating Medicines Partnership ⁸ and Michelle Petri ⁹, ¹Johns Hopkins University, Baltimore, ²University of Maryland, Baltimore, ³NYU School of Medicine, New York, ⁴New York University School of Medicine, Ney York, ⁵New York University School of Medicine, New York, ⁶University of Houston, Houston, ⁷Biomedical Engineering, University of Houston, Houston, TX, ⁸Multiple Organizations, USA, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) complicates up to 60% of patients with systemic lupus erythematosus (SLE) and carries a high morbidity and mortality. The definitive diagnosis…
Abstract Number: 9 • 2019 ACR/ARP Annual Meeting
Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus
Julian Torres Vazquez¹, Alejandro Corzo Cruz ², David Alberto Comoto Santacruz ² and Omar Eloy Muñoz Monroy ¹, ¹Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Distrito Federal, Mexico, ²Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Mexico
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a wide range of systemic dysfunctions as well as an elevated erythrocyte sedimentation rate. Chemokine CXCL 10…
Abstract Number: 246 • 2019 ACR/ARP Annual Meeting
Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus
Nnenna Ezeh¹, Trevor McKown ¹, Shivani Garg ¹ and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients of color are more likely to have systemic lupus erythematosus (SLE) and a smoking history. Prior literature notes that both smoking and race…
Abstract Number: 683 • 2019 ACR/ARP Annual Meeting
Biologic Differences Between Type 1 and 2 Lupus
Megan Clowse¹, Jennifer Rogers ¹, Amanda Eudy ¹, Lisa Criscione-Schreiber ¹, Jayanth Doss ¹, Rebecca Sadun ¹, Kai Sun ¹, Micah McClain ², Ephraim Tsalik ³, Chris Woods ², David Pisetsky ⁴, Prathyusha Bachali ⁵, Amrie Grammer ⁶, Michelle Catalina ⁵ and Peter Lipsky ⁷, ¹Duke University, Durham, ²Duke University & Duke Center for Applied Genomics & Precision Medicine, Durham, ³Duke University, Duke Center for Applied Genomics & Precision Medicine, Durham VA, Durham, ⁴Duke University, Durham VAMC, Durham, ⁵AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, VA, ⁶AMPEL BioSolutions and the RILITE Research Institute, Charlottesville, ⁷AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: The manifestations of systemic lupus erythematosus (SLE) can be divided into categories according to a recently proposed model: a category of classic active autoimmune-driven…
Abstract Number: 944 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Dapirolizumab Pegol in Patients with Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Placebo-Controlled Study
Richard Furie¹, Ian Bruce ², Thomas Dörner ³, Manuel Gustavo Leon ⁴, Piotr Leszczyński ⁵, Murray Urowitz ⁶, Birgit Haier ⁷, Claire Brittain ⁸, Jiajun Liu ⁹, Catherine Barbey ¹⁰ and Christian Stach ⁷, ¹Northwell Health, Great Neck, NY, ²University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ³Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴Investigaciones Clínicas, Lima, Peru, ⁵Poznań University of Medical Sciences, Poznań, Poland, ⁶University Health Network, University of Toronto, Toronto, ON, Canada, ⁷UCB Pharma, Monheim, Germany, ⁸UCB Pharma, Slough, United Kingdom, ⁹Biogen, Cambridge, MA, ¹⁰Biogen, Baar, Switzerland
Background/Purpose: Dapirolizumab pegol (DZP) is a polyethylene glycol-conjugated Fab’ fragment, which targets CD40 ligand and is in development for the treatment of systemic lupus erythematosus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].